CREATE Medicines Demonstrates Complete B Cell Depletion and Repeatable Dosing in Non-human Primates with In Vivo CAR-T Platform

CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo CAR therapy, today announced new ...
PharmiWeb

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen ...

BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

Detailed price information for Biovaxys Technology Corp (BIOV-CN) from The Globe and Mail including charting and trades.
The Manila Times

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

In November 2025, Nurix appointed accomplished biopharmaceutical leader Roger Dansey, M.D., to its Board of Directors, adding ...
Targeted Oncology

FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma

The FDA has granted fast track designation (FTD) to LBL-034, an investigational GPRC5D/CD3 bispecific T-cell engager (BiTE), for patients with relapsed/refractory multiple myeloma (R/R MM).

Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers

Cash-rich Cullinan Therapeutics stock: zipalertinib NDA in Q1 2026 plus CLN-978 and CLN-049 AML catalysts. Read here for more analysis.
eLife

Cryo-EM structure revealed a novel F-actin binding motif in a Legionella pneumophila lysine fatty acyltransferase

A novel F-actin-binding motif consisting of an α-helix hairpin from a Legionella pneumophila lysine fatty acyltransferase has the potential to be developed as an F-actin probe.